KOSDAQBiotech & Pharma166480

Corestemchemon

₩1,372▲ 1.25%2026-11-18 close
Market Cap
₩72.5B
Turnover
₩600M
Volume
460K
Shares out.
52.9M
PER
—
PBR
1.6×
EPS
-₩586
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Neuronata-R Approval Puts Commercial Execution to the Test

Conditional approval of Neuronata-R has set up domestic commercial supply, but reported results remain loss-making and revenue fell for three consecutive years through 2025.

  1. 1

    Domestic approval: Neuronata-R received a change approval from MFDS in May 2026, with a confirmatory trial and a final study report as conditions.

  2. 2

    Results: FY2025 revenue was KRW 20.2 billion and operating loss was KRW 21.2 billion. Q3 2026 revenue rose 60.4% year on year to KRW 5.77 billion, but operating loss of KRW 4.68 billion and net loss attributable to controlling shareholders of KRW 4.53 billion continued.

  3. 3

    CRO: According to the company, new preclinical CRO orders in H1 2026 reached KRW 15.2 billion, up 69% year on year.

  4. 4

    Balance sheet: The debt ratio fell from 301.0% in 2023 to 103.7% in 2025, and the company says inflows were used to repay borrowings.

  5. 5

    US strategy: The company announced it completed an FDA Type C meeting and is pursuing a two-track plan of a Phase 3b IND and an accelerated BLA filing.

02

Business structure

CORESTEM CHEMON runs two pillars: cell therapy development and non-clinical CRO services. The company operates on two pillars, preclinical CRO and cell therapy development.

Its lead asset, Neuronata-R, is an autologous bone-marrow-derived mesenchymal stem cell therapy for ALS, and it received a change approval for the product license from MFDS in May 2026. The approval rests on a follow-up confirmatory trial and a final study report.

The key to the indication is a narrower patient population. The Phase 3 trial did not reach statistical significance across all patients, but in the slow-progressor subgroup the primary efficacy index and the secondary index were met. A neurofilament light chain (NfL) reduction was also presented.

On production, the Osong plant secured a manufacturing change permit for advanced biopharmaceuticals and a cell processing facility permit in sequence.

Segment sales are thin: a report from October 2025 said sales in the biopharmaceutical segment, which includes Neuronata-R, fell to the KRW 100 million range from KRW 600 million a year earlier.

In CRO, demand is growing mainly for medical device clients, and the company signed a contract with a Vietnamese university hospital. Demand for Neuronata-R is also expanding toward overseas ALS patients.

Follow-on programs include neuromyelitis optica, with idiopathic pulmonary fibrosis also being prepared for a clinical trial application.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.6B-₩7.5B−208.0%
2025Q4₩4.9B-₩3.1B−62.4%
2026Q1₩4.3B-₩6B−137.7%
2026Q2₩5.4B-₩4.3B−79.3%
2026Q3₩5.8B-₩4.7B−81.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩46.3B-₩6B₩1B−13.0%2.4%89.6%
2023₩33.7B-₩19.7B-₩17.7B−58.5%−90.2%301.0%
2024₩28.8B-₩22B-₩26.3B−76.6%−54.0%141.7%
2025₩20.2B-₩21.2B-₩26.8B−105.3%−48.6%103.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a disclosed annual basis, revenue fell from KRW 46.3 billion in 2022 to KRW 33.7 billion in 2023 (down 27.3%), KRW 28.8 billion in 2024 (down 14.5%) and KRW 20.2 billion in 2025 (down 29.9%).

Revenue declined for three consecutive years from 2023 through 2025, with 2022 the largest year and 2025 the smallest in the 2022-2025 period. Operating loss widened from KRW 6.01 billion in 2022 to KRW 19.7 billion in 2023 and KRW 22 billion in 2024, then narrowed to KRW 21.2 billion in 2025.

The operating margin moved from -13.0% in 2022 to -58.5% in 2023, -76.6% in 2024 and -105.3% in 2025. Because revenue fell faster than the loss narrowed, the margin deteriorated.

Net income attributable to controlling shareholders turned from KRW 1 billion in 2022 to a net loss of KRW 17.7 billion in 2023, then KRW 26.3 billion in 2024 and KRW 26.8 billion in 2025. Net income including non-controlling interests followed the same pattern of losses since 2023.

The debt ratio peaked at 301.0% in 2023 before falling to 103.7% in 2025, when total equity was KRW 55.2 billion and total liabilities were KRW 57.2 billion. The company has said it used inflows to repay borrowings, which lowered the debt ratio.

Operating cash flow improved from a negative KRW 21.1 billion in 2024 to negative KRW 13.9 billion in 2025.

Quarterly revenue rose from KRW 3.6 billion in Q3 2025 to KRW 4.95 billion in Q4 (up 37.5% quarter on quarter), dipped to KRW 4.35 billion in Q1 2026 (down 12.2%), then increased to KRW 5.4 billion in Q2 and KRW 5.77 billion in Q3, two consecutive quarterly gains.

Operating loss was KRW 7.49 billion in Q3 2025, KRW 3.09 billion in Q4, KRW 5.99 billion in Q1 2026, KRW 4.28 billion in Q2 and KRW 4.68 billion in Q3 2026. Q3 2026 losses widened from the prior quarter but narrowed from a year earlier.

The sum of net losses attributable to controlling shareholders over the last four quarters was KRW 25.2 billion. A report by The Bell said consolidated cost of sales as a share of revenue fell from 136% to 102.5% in Q2 2026, and gross loss narrowed from about KRW 1.56 billion to about KRW 0.13 billion.

05

Industry analysis

The ALS treatment market is dominated by therapies that slow progression, which the company views as leaving a large unmet need for disease-modifying options. The company sees most ALS treatments as limited to delaying symptoms, leaving a relatively large unmet medical need.

The United States is widely reported to have one of the largest ALS patient populations, which is why US entry is emphasized. Conditional approvals do exist: Biogen's ALS drug is often cited as an example that won FDA approval on NfL improvement despite missing its primary endpoint.

However, a Pharm Edaily analysis put the conditional approval probability for Neuronata-R at only 18%, given that two of 11 therapies received conditional approval over seven years. Domestically, a VC bio analyst read the KRW 100 million range of Neuronata-R sales as a sign of limited prescribing.

In cell therapy manufacturing, facilities and quality systems are decisive. The company said the Osong plant was designed to meet commercial GMP standards of both MFDS and the US FDA. In CRO, rising orders from medical device clients are broadening preclinical demand.

Compared with large biopharma and CDMO companies, the scale gap is wide, and the presence of an in-house cell therapy pipeline is presented as the differentiator.

06

Outlook

The nearest checkpoint is the restart of production. The company plans to resume production once it receives the new plant approval, and expects domestic supply to normalize as early as early 2027, depending on the review schedule. It expects full-scale drug sales to begin then.

Domestic commercial production will start after a comparability evaluation between the existing Yongin GMP plant and the Osong plant. Overseas, the company plans to brief overseas ALS specialists once supply resumes to expand overseas patient intake.

The US plan runs two tracks: a Phase 3b IND approval and an accelerated approval BLA filing, pursued at the same time. The company said it completed a Type C meeting with the FDA on follow-on development direction for the ALS drug. It also aimed to confirm the accelerated approval path and the use of NfL.

Securing RMAT designation could bring close FDA consultation and faster review in development and approval. Revenue recognition from H1 2026 contracts is expected to pick up from the second half.

Much of the order backlog at end-June is expected to be recognized in sequence over the second half and the first half of 2027. The KRW 26.1 billion rights offering funds are planned for approval readiness, quality control, a dedicated cell therapy GMP facility, and global trial and approval execution.

07

Valuation

PER
—
PBR
1.6×
ROE
-61.6%
EPS
-₩586
BPS
₩853
Dividend per share
₩0

Because net losses have continued over the last four quarters, a price-to-earnings multiple cannot be calculated. The price-to-book ratio sits above 1x, which means the stock trades at a premium to net assets, reflecting value beyond assets such as approval expectations and the pipeline.

No dividend has been paid, so the dividend yield is below the industry average. Past profitable-period multiple bands are hard to use as a direct benchmark given losses since 2023. With the operating margin at -105.3% in 2025, multiple comparisons will depend on the pace of revenue recovery and margin improvement.

Total equity of KRW 55.2 billion at end-2025 is a disclosed reference point for asset value. Because the premium changes with the share price, the current multiples shown alongside the report are the relevant factual comparison.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Approval-based commercial production setup

The May 2026 change approval provides the basis for domestic sales. The Osong plant holds manufacturing and cell processing permits, and the company says overseas treatment inquiries continue. The company argues that the market structure lets approval translate directly into sales.

CRO order recovery and lower cost ratio

According to the company, H1 2026 new preclinical CRO orders reached KRW 15.2 billion, up 69% year on year. Services concentrate in the months to a year after contract signing, so the company expects revenue recognition to continue in H2. Cost of sales as a share of revenue fell from 136% to 102.5% in Q2.

Balance sheet improvement

The debt ratio fell from 301.0% in 2023 to 103.7% in 2025. The company says inflows were used to repay borrowings. Operating cash flow deficit narrowed from negative KRW 21.1 billion in 2024 to negative KRW 13.9 billion in 2025.

09

Bear factors

Limits of clinical evidence

The Phase 3 trial missed its primary endpoint across all patients. The Phase 2 trial did not reach statistical significance on overall survival.

The slow-progressor results come from a subgroup analysis, and the 5.6-year survival gain was measured against an external control, which limits its weight as randomized evidence.

Continued losses and small revenue base

FY2025 revenue was KRW 20.2 billion, down for three consecutive years, with an operating loss of KRW 21.2 billion. Operating losses have run for five consecutive quarters from Q3 2025 through Q3 2026, and net losses attributable to controlling shareholders over the last four quarters total KRW 25.2 billion. Biopharmaceutical segment sales were reported at the KRW 100 million level.

Approval odds and funding burden

Pharm Edaily put the conditional approval odds at 18%, based on approval rates among similar therapies. A VC analyst read the KRW 100 million-level sales as a sign of weak prescribing. US trial costs of several hundred billion won are cited, and funding needs are tied to the earnings path.

10

Risk factors

Approval condition risk

The change approval carries conditions requiring a confirmatory trial and result submission. Failing to meet them could reopen the question of whether approval is maintained. Pharm Edaily noted that without approval, domestic sales would likely stop.

Funding and trial costs

US Phase 3b and BLA preparation is cited with costs in the hundreds of billions of won. Without partnering income, the company must fund it alone, which could add pressure for further financing. Proceeds from the KRW 26.1 billion rights offering are planned for approval readiness and production facilities.

Timing of earnings turnaround

CRO revenue recognition is concentrated in the second half, so quarterly volatility could be high. Q3 2026 still posted an operating loss of KRW 4.68 billion. Because backlog is recognized in sequence, the timing of a return to profit remains uncertain.

11

What to watch next

  1. After December 2026 (per disclosure)

    Disclosure of FDA Phase 3b IND clearance and the BLA accelerated approval filing timeline. The start of US trials and how costs are funded are the next checkpoints.

  2. Early 2027

    Comparability evaluation results for the Osong plant and whether domestic supply resumes. The shift to commercial production is the starting point for revenue recovery.

  3. End of March 2027

    Filing of the FY2026 annual report. Check annual revenue and operating loss, the scale of Neuronata-R sales, and recognition of the CRO order backlog.

  4. Mid-May 2027

    Q1 2027 quarterly report. Whether operating losses persist and the trend in operating margin are the next checkpoints.

12

Overall view

CORESTEM CHEMON has built a commercial production framework through the domestic change approval for Neuronata-R and the Osong plant permits. Reported results, however, remain loss-making, with FY2025 revenue of KRW 20.2 billion down for three consecutive years and an operating loss of KRW 21.2 billion.

Q3 2026 revenue rose 60.4% year on year to KRW 5.77 billion, a sign of recovery, but operating loss of KRW 4.68 billion and a net loss attributable to controlling shareholders of KRW 4.53 billion mean a profit turnaround has not yet appeared.

Strengths include the approval-based production setup, the CRO order recovery (KRW 15.2 billion in H1 2026) and the lower debt ratio. Weaknesses include the missed Phase 3 primary endpoint, low conditional approval odds and the funding burden of US trials.

The next checkpoints are the domestic supply restart in early 2027, the operating margin in the FY2026 annual report, and the FDA follow-on trial timeline.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. mt.co.kr
  2. m.thebell.co.kr
  3. m.yakup.com
  4. cro.corestemchemon.com
  5. etoday.co.kr
  6. biotimes.co.kr
  7. pharm.edaily.co.kr
  8. biotimes.co.kr
  9. m.news.nate.com
  10. m.news.nate.com
  11. pharm.edaily.co.kr
  12. mt.co.kr
  13. v.daum.net
  14. mt.co.kr
  15. mt.co.kr
  16. supple.kr
  17. moneyplan.ai.kr
  18. ncbi.nlm.nih.gov

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis